These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 22164966)
1. Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy. Jagani HV; Josyula VR; Hariharapura RC; Palanimuthu VR; Gang SS Arzneimittelforschung; 2011; 61(10):577-86. PubMed ID: 22164966 [TBL] [Abstract][Full Text] [Related]
2. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating. Jagani HV; Josyula VR; Palanimuthu VR; Hariharapura RC; Gang SS Eur J Pharm Sci; 2013 Mar; 48(4-5):611-8. PubMed ID: 23291045 [TBL] [Abstract][Full Text] [Related]
3. Preparation of polyethyleneimine incorporated poly(D,L-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Katas H; Cevher E; Alpar HO Int J Pharm; 2009 Mar; 369(1-2):144-54. PubMed ID: 19010405 [TBL] [Abstract][Full Text] [Related]
4. A nanoformulation of siRNA and its role in cancer therapy: in vitro and in vivo evaluation. Jagani H; Rao JV; Palanimuthu VR; Hariharapura RC; Gang S Cell Mol Biol Lett; 2013 Mar; 18(1):120-36. PubMed ID: 23271435 [TBL] [Abstract][Full Text] [Related]
5. Polymeric nanoparticles for siRNA delivery and gene silencing. Patil Y; Panyam J Int J Pharm; 2009 Feb; 367(1-2):195-203. PubMed ID: 18940242 [TBL] [Abstract][Full Text] [Related]
6. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Cun D; Jensen DK; Maltesen MJ; Bunker M; Whiteside P; Scurr D; Foged C; Nielsen HM Eur J Pharm Biopharm; 2011 Jan; 77(1):26-35. PubMed ID: 21093589 [TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of polymeric nanoparticles for siRNA delivery to down-regulate the expressions of exogenous and endogenous target genes. Huang W; Lv M; Gao ZG; Jin MJ; Xu YJ; Yu XD; Jin ZH; Yin XZ Pharmazie; 2012 Aug; 67(8):676-80. PubMed ID: 22957431 [TBL] [Abstract][Full Text] [Related]
9. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer. Kala S; Mak AS; Liu X; Posocco P; Pricl S; Peng L; Wong AS J Med Chem; 2014 Mar; 57(6):2634-42. PubMed ID: 24592939 [TBL] [Abstract][Full Text] [Related]
10. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594 [TBL] [Abstract][Full Text] [Related]
11. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Das J; Das S; Paul A; Samadder A; Bhattacharyya SS; Khuda-Bukhsh AR Toxicol Lett; 2014 Mar; 225(3):454-66. PubMed ID: 24440344 [TBL] [Abstract][Full Text] [Related]
12. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells. Heo MB; Cho MY; Lim YT Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635 [TBL] [Abstract][Full Text] [Related]
14. Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. Frede A; Neuhaus B; Klopfleisch R; Walker C; Buer J; Müller W; Epple M; Westendorf AM J Control Release; 2016 Jan; 222():86-96. PubMed ID: 26699423 [TBL] [Abstract][Full Text] [Related]
15. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Zeng P; Xu Y; Zeng C; Ren H; Peng M Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597 [TBL] [Abstract][Full Text] [Related]
16. NaCl induced high cationic hydroxyethylated cholesterol-based nanoparticle-mediated synthetic small interfering RNA transfer into prostate carcinoma PC-3 cells. Hattori Y; Yoshizawa T; Koga K; Maitani Y Biol Pharm Bull; 2008 Dec; 31(12):2294-301. PubMed ID: 19043216 [TBL] [Abstract][Full Text] [Related]
17. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Jensen DK; Jensen LB; Koocheki S; Bengtson L; Cun D; Nielsen HM; Foged C J Control Release; 2012 Jan; 157(1):141-8. PubMed ID: 21864597 [TBL] [Abstract][Full Text] [Related]
18. SiRNA drug delivery by biodegradable polymeric nanoparticles. Yuan X; Li L; Rathinavelu A; Hao J; Narasimhan M; He M; Heitlage V; Tam L; Viqar S; Salehi M J Nanosci Nanotechnol; 2006; 6(9-10):2821-8. PubMed ID: 17048488 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of SOX9 genes and anti-Cbfa-1 siRNA coated onto PLGA nanoparticles for chondrogenesis of human MSCs. Jeon SY; Park JS; Yang HN; Woo DG; Park KH Biomaterials; 2012 Jun; 33(17):4413-23. PubMed ID: 22425025 [TBL] [Abstract][Full Text] [Related]
20. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical. Svenson S; Case RI; Cole RO; Hwang J; Kabir SR; Lazarus D; Lim Soo P; Ng PS; Peters C; Shum P; Sweryda-Krawiec B; Tripathi S; van der Poll D; Eliasof S Mol Pharm; 2016 Mar; 13(3):737-47. PubMed ID: 26835715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]